Skip to main content
Premium Trial:

Request an Annual Quote

Acclerys Stock Climbs 6 Percent After Analyst Begins Coverage, Lauds Firm s Clean Balance Sheet

NEW YORK, March 14 (GenomeWeb News) - Shares in Accelrys were up 6 percent, or $.30, at $5.30 in mid-afternoon trading after a securities analyst began covering the company today and gave the stock a 'Buy' rating.


"We believe Accelrys is a sound nanotechnology play," Braswell said in a statement today. "With $59.1 million in gross cash and no long-term debt, Accelrys has arguably the cleanest balance sheet among our coverage universe of companies in the nanotech space.


"The company also has a large, stable base of blue chip customers in the pharmaceutical and materials industries," Braswell added.


J. Andrew Braswell, an analyst with Newbridge Securities, said he expects the stock to reach $9 in 12 months. He said that shares in Accelrys are "currently undervalued, in our opinion."

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.